Skip to main content


We're creating a new version of this page. See preview

  • Oral presentation
  • Open Access

Differential expression of miR-4520a is associated with gain of function mutations in Familial Mediterranean Fever (FMF)

  • 1,
  • 2,
  • 3,
  • 2,
  • 4,
  • 5,
  • 5,
  • 5,
  • 6, 7,
  • 4,
  • 2,
  • 1, 5,
  • 6, 7,
  • 7, 8 and
  • 1
Pediatric Rheumatology201513 (Suppl 1) :O10

  • Published:


  • Colchicine
  • Familial Mediterranean Fever
  • THP1 Cell
  • Familial Mediterranean Fever Patient
  • Dual Luciferase Assay


MicroRNA signature of THP1 cells revealed a 5.9-fold decreased expression of miR-4520a following siRNA-mediated knockdown of MEFV gene that encodes pyrin [1].


We herein sought to validate the expression levels of miR-4520a in monocytes isolated from peripheral blood mononuclear cells (PBMCs) of FMF patients.


Dual luciferase assay was used to validate a predicted miR-4520a recognition element in the 3'UTR region of the Rheb gene. The expression levels of pyrin, miR-4520a and its putative target Rheb were validated in monocytes from FMF patients (n=9) and compared with healthy controls (n=8). Patients were off colchicine for two days (attack-free period) and monocytes were isolated from PBMCs. Total RNA together with the respective miRNA-enriched fractions were isolated from monocytes and used for mRNA and miR-4520a quantitation by real-time PCR using the 2-ΔΔCt method after normalizing to 18S RNA and RNU6B genes, respectively. Protein levels of pyrin and Rheb were detected by western blotting.


The relative expression levels of miR-4520a were variable among FMF patients and not significantly different between patients and controls. However, when patients that did not harbor any mutations in MEFV were excluded from the analyses, the expression of miR-4520a was statistically different between FMF patients and controls (p<0.05), indicating an association between miR-4520a expression and mutations in the MEFV gene. Moreover, stratification of patients group by genotype revealed an intriguing difference in miR-4520a relative expression, with carriers of M694V variant (combined group of homozygotes, heterozygotes and compound heterozygotes) showing the highest increase (p<0.05). Subsequent comparison between the M694V group and healthy controls showed a significant increase in miR-4520a expression levels that remained significant even after bonferroni correction (p<0.01). Interestingly, one of the homozygote M694V patients with the highest fold change in miR-4520a expression (FC=7.8) experienced an FMF-attack while on study, with a concomitant decrease in miR-4520a relative expression (FC=0.45). Bio-informatic analyses showed that miR-4520a is predicted to target genes implicated in autophagy through regulation of Rheb/mTOR signaling. Expression levels of Rheb were confirmed by luciferase reporter gene assays providing further evidence that Rheb is a direct target of miR-4520a (p<0.01). Validation of pyrin and Rheb protein expression levels in monocytes from FMF patients is in progress.


Our findings provide initial evidence that Rheb is a valid target of miR-4520a and suggest that a dysfunctional pyrin due to gain of function mutations with a dosage effect [2], especially of M694V variant, may be associated with an increase in miR-4520a expression levels, thus contributing to deregulated mTOR signaling and subsequently IL-1β release [3].

Authors’ Affiliations

University of Crete, Medical School, Internal Medicine, Heraklion, Greece
German Rheumatism Research Center (DRFZ), Berlin, Germany
German Rheumatism Research Center (DRFZ), Bioinformatics, Berlin, Germany
Charité University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany
University Hospital of Heraklion, Clinic of Rheumatology, Heraklion, Greece
University of Crete, Medical School, Biochemistry, Heraklion, Greece
Institute of Molecular Biology and Biotechnology, Foundation for research and Technology of Hellas, Heraklion, Greece
University of Athens, Medical School, Athens, Greece


  1. Mashreghi M F, Latsoudis H, Gruen J, et al: Ann Rheum Dis. 2014, 73: 344-345.View ArticleGoogle Scholar
  2. Chae J J, Cho Y-H, Lee G-S, et al: Immunity. 2011, 34: 755-768. 10.1016/j.immuni.2011.02.020.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Schmitz F, Heit A, Dreher S, et al: Eur J Immun. 2008, 38: 2981-2992. 10.1002/eji.200838761.View ArticleGoogle Scholar


© Latsoudis et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.